MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) (“Constellation”) have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00 per share in cash. This transaction bolsters MorphoSys’s position in hematology-oncology and expands our reach into solid tumors, further advancing our mission in the fight against cancer.
MorphoSys also announced that it has entered into a strategic funding partnership with Royalty Pharma plc (Nasdaq: RPRX), enabling us to fund our growth for years to come.
MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals
MorphoSys to Acquire Constellation Pharmaceuticals
Events and Presentations
8:00 AM EST / 2:00 PM CEST, 06/02/2021 - MorphoSys to Acquire Constellation Pharmaceuticals Investor Conference Call
MorphoSys SEC Filings
Constellation Pharmaceuticals SEC Filings